Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629602 | 0.90 | KMT2A (0.53) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL8853748 | 0.88 | EPHX2 (0.70) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL434490 | 0.83 | EPHX2 (0.77) | KMT2ALMNAEPHX2MMP12MAPT | |
| SCHEMBL8853758 | 0.81 | LMNA (0.54) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL19506843 | 0.81 | KMT2A (0.46) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL8853550 | 0.80 | HDAC1 (0.57) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL5507140 | 0.80 | HDAC1 (0.57) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL8853694 | 0.80 | MAOA (0.57) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL3328663 | 0.78 | HDAC1 (0.55) | KMT2ATP53HDAC1HDAC8HDAC6 | |
| SCHEMBL5311151 | 0.76 | HTT (0.73) | KMT2ATP53HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| EP-3182973-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2016027249-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0657407-B1 | Process for the preparation of 3-fluoro-4,6-dichlorotoluene | BAYER AG (DE) | 1997-12-10 | — | — | EP | disclosed |
| US-5475164-A | Process for preparing 3-fluoro-4,6-dichlorotoluene | BAYER AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0657407-A1 | Process for the preparation of 3-fluoro-4,6-dichlorotoluene | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0324181-B1 | PROCESS FOR THE PREPARATION OF BENZOTHIAZEPINONE DERIVATIVES | BAYER AG (DE) | 1991-11-27 | — | — | EP | disclosed |
| US-4948886-A | Process for the preparation of benzothiazepinone derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1990-08-14 | — | — | US | disclosed |
| EP-0292824-B1 | PROCESS FOR THE NUCLEAR CHLORINATION OF AROMATIC HYDROCARBONS | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4851596-A | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0324181-A1 | Process for the preparation of benzothiazepinone derivatives | BAYER AG (DE) | 1989-07-19 | — | — | EP | disclosed |
| EP-0292824-A1 | Process for the nuclear chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | KMT2A 3610/4885TP53 4673/4885HDAC1 1853/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | KMT2A 2573/4885TP53 4607/4885HDAC1 2176/4885 |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KMT2A 2496/4885TP53 4650/4885HDAC1 2373/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | KMT2A 1748/4885TP53 4826/4885HDAC1 1617/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | KMT2A 3610/4885TP53 4673/4885HDAC1 1853/4885 |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | KMT2A 3288/4885TP53 1357/4885HDAC1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.